EGFR and neoplasm: In conclusion, we demonstrated that targeting EGFR-integrin αvβ3 interaction by CL4 aptamer, results in inhibition of VM and tumor growth in TNBCs resistant to both erlotinib and cetuximab, raising the possibility of a new aptamer-based therapeutic approach to impair the phenomenon of vasculogenesis in TNBC.